NoviThera Initiates Preclinical Studies for Novel Monoclonal Antibody Targeting Psoriasis
Key Insights
NoviThera ApS (search), a subsidiary of Nordicus Partners Corporation (search), has initiated the first efficacy animal studies for a novel monoclonal antibody (search) treatment targeting psoriasis (search).
The company's approach focuses on targeting an endogenous cathelicidin antimicrobial polypeptide that drives psoriasis (search) pathogenesis through immune cell activation and inflammatory cytokine production.
Two preclinical mouse studies are currently underway, including development of a humanized genetic mouse model, with toxicity studies planned for 2027 and patient trials anticipated in 2028.
NoviThera ApS (search), a majority-owned subsidiary of Nordicus Partners Corporation (search), has launched its first efficacy animal studies for a novel monoclonal antibody (search) treatment targeting psoriasis (search). The Danish biotech company is developing what it describes as a potentially curative approach to the chronic inflammatory skin condition that affects millions worldwide.
Novel Therapeutic Mechanism
NoviThera's approach centers on targeting an endogenous cathelicidin antimicrobial polypeptide that the company has identified as a key driver of psoriasis (search) pathogenesis. According to the company, psoriasis forms when high concentrations of this polypeptide are present, and their hypothesis suggests that removal or reduction of this polypeptide could cure and prevent disease progression.
The targeted polypeptide is produced by various cells, including keratinocytes, and plays a crucial role in the innate immune response. While it normally exhibits antimicrobial, immunomodulatory, and wound-healing properties, in psoriasis (search) it takes on a pro-inflammatory role that exacerbates the condition.
Pathological Pathway
The company has detailed the mechanism by which the polypeptide drives psoriasis (search) development. The polypeptide binds to self-DNA and self-RNA released from damaged keratinocytes, protecting these nucleic acids from degradation and allowing them to activate plasmacytoid dendritic cells through Toll-like receptor 9 or TLR7/8 (search).
Activated plasmacytoid dendritic cells produce large amounts of type I interferons, particularly IFN-α, which then activates myeloid dendritic cells. These cells present antigens and release cytokines including IL-12 and IL-23, promoting differentiation of Th1 and Th17 cells. This cascade leads to secretion of IL-17 (search), IL-22 (search), IFN-γ, and TNF-α (search), ultimately driving keratinocyte hyperproliferation and the characteristic psoriatic plaque phenotype.
Preclinical Development Program
NoviThera is currently conducting two preclinical mouse studies to establish biological proof of concept. The first study involves intradermal injections at plaque sites, with animals that develop psoriasis (search) subsequently treated with the company's proprietary monoclonal antibody (search) to demonstrate biological efficacy.
The second study focuses on developing a humanized genetic mouse model capable of producing the target polypeptide. This development is necessary because the polypeptide is only produced in humans and not in animals, which will enable more comprehensive animal studies.
Development Timeline
Following completion of the current studies, NoviThera plans to conduct toxicity studies during 2027, with patient trials anticipated to begin in 2028. The invention was developed by Allan Wehnert, CEO of NoviThera, in conjunction with Nordicus Partners Corporation (search).
Current Treatment Landscape
Psoriasis (search) is currently managed through topical creams, phototherapy, and in severe cases, interleukin antibodies. The condition is characterized by well-demarcated erythematous plaques with silvery scale on extensor surfaces, scalp, sacral area, and nails, presenting with pitting and onycholysis.
NoviThera was formed in October 2025 with the specific objective to research and develop this novel monoclonal antibody (search) therapy. The company acquired the drug development rights from Alteral Therapeutics (search) in Denmark, with Allan Wehnert serving as CEO of the newly-formed entity.